IL175674A0 - Method to improve the efficacy of therapeutic radiolabeled drugs - Google Patents
Method to improve the efficacy of therapeutic radiolabeled drugsInfo
- Publication number
- IL175674A0 IL175674A0 IL175674A IL17567406A IL175674A0 IL 175674 A0 IL175674 A0 IL 175674A0 IL 175674 A IL175674 A IL 175674A IL 17567406 A IL17567406 A IL 17567406A IL 175674 A0 IL175674 A0 IL 175674A0
- Authority
- IL
- Israel
- Prior art keywords
- efficacy
- improve
- radiolabeled drugs
- therapeutic radiolabeled
- therapeutic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52847303P | 2003-12-11 | 2003-12-11 | |
| PCT/IB2004/004428 WO2005056058A2 (en) | 2003-12-11 | 2004-12-13 | Radiosensitizer conjugate to improve the efficacy of radiolabeled drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL175674A0 true IL175674A0 (en) | 2006-09-05 |
Family
ID=34676848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL175674A IL175674A0 (en) | 2003-12-11 | 2006-05-16 | Method to improve the efficacy of therapeutic radiolabeled drugs |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1691838A2 (en) |
| JP (1) | JP2007528874A (en) |
| KR (1) | KR20060118542A (en) |
| CN (1) | CN101031319A (en) |
| AU (1) | AU2004296621A1 (en) |
| BR (1) | BRPI0417517A (en) |
| CA (1) | CA2546057A1 (en) |
| CR (1) | CR8439A (en) |
| EC (1) | ECSP066618A (en) |
| IL (1) | IL175674A0 (en) |
| MX (1) | MXPA06006683A (en) |
| NO (1) | NO20063207L (en) |
| RU (1) | RU2006124510A (en) |
| WO (1) | WO2005056058A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI568453B (en) * | 2011-11-22 | 2017-02-01 | 原創生醫股份有限公司 | A drug carrier with chelating complex micelles and the application thereof |
| CN106975078B (en) * | 2017-03-31 | 2020-11-10 | 国家纳米科学中心 | Application of nano material containing gadolinium polytungstate as sensitizer |
| WO2024013272A1 (en) * | 2022-07-13 | 2024-01-18 | Universite De Montpellier | Combined therapy with nanoparticles and radiopharmaceuticals |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR022404A1 (en) * | 1999-01-25 | 2002-09-04 | Photogen Inc | METHOD AND AGENTS FOR IMPROVED RADIATION THERAPY |
| WO2001072958A2 (en) * | 2000-03-28 | 2001-10-04 | Beth Israel Deaconess Medical Center | Bladder cancer-specific peptides for diagnosis and therapy |
| BR0206985A (en) * | 2001-01-29 | 2005-04-19 | Idec Pharma Corp | Modified Antibodies and Methods of Use |
| EP1534336A4 (en) * | 2002-08-15 | 2005-12-14 | Human Genome Sciences Inc | Antibodies that immunospecifically bind to trail receptors |
-
2004
- 2004-12-13 WO PCT/IB2004/004428 patent/WO2005056058A2/en active Search and Examination
- 2004-12-13 RU RU2006124510/15A patent/RU2006124510A/en not_active Application Discontinuation
- 2004-12-13 BR BRPI0417517-4A patent/BRPI0417517A/en not_active IP Right Cessation
- 2004-12-13 EP EP04817629A patent/EP1691838A2/en not_active Withdrawn
- 2004-12-13 AU AU2004296621A patent/AU2004296621A1/en not_active Abandoned
- 2004-12-13 MX MXPA06006683A patent/MXPA06006683A/en unknown
- 2004-12-13 CA CA002546057A patent/CA2546057A1/en not_active Abandoned
- 2004-12-13 KR KR1020067011322A patent/KR20060118542A/en not_active Application Discontinuation
- 2004-12-13 JP JP2006543664A patent/JP2007528874A/en not_active Withdrawn
- 2004-12-13 CN CNA2004800369951A patent/CN101031319A/en active Pending
-
2006
- 2006-05-16 IL IL175674A patent/IL175674A0/en unknown
- 2006-06-07 CR CR8439A patent/CR8439A/en unknown
- 2006-06-08 EC EC2006006618A patent/ECSP066618A/en unknown
- 2006-07-10 NO NO20063207A patent/NO20063207L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007528874A (en) | 2007-10-18 |
| EP1691838A2 (en) | 2006-08-23 |
| AU2004296621A1 (en) | 2005-06-23 |
| KR20060118542A (en) | 2006-11-23 |
| MXPA06006683A (en) | 2006-08-11 |
| WO2005056058A2 (en) | 2005-06-23 |
| BRPI0417517A (en) | 2007-03-06 |
| ECSP066618A (en) | 2006-10-25 |
| NO20063207L (en) | 2006-07-10 |
| RU2006124510A (en) | 2008-01-20 |
| WO2005056058A3 (en) | 2006-04-13 |
| CR8439A (en) | 2006-12-07 |
| CN101031319A (en) | 2007-09-05 |
| CA2546057A1 (en) | 2005-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB0303910D0 (en) | Therapeutic agents | |
| GB0308318D0 (en) | Therapeutic agents | |
| GB0316912D0 (en) | Therapeutic treatment | |
| GB0320806D0 (en) | Therapeutic treatment | |
| GB0310401D0 (en) | Therapeutic agent | |
| GB0305150D0 (en) | Use of therapeutic compounds | |
| GB0323378D0 (en) | Therapeutic agent | |
| GB0326768D0 (en) | Generation of therapeutic microfoam | |
| GB0311201D0 (en) | Therapeutic agents | |
| GB0301350D0 (en) | Therapeutic agents | |
| IL175674A0 (en) | Method to improve the efficacy of therapeutic radiolabeled drugs | |
| EP1670755A4 (en) | Pyrovalerone analogs and therapeutic uses thereof | |
| GB0329275D0 (en) | Therapeutic treatment | |
| GB0307863D0 (en) | Therapeutic treatment | |
| GB0313772D0 (en) | Therapeutic treatment | |
| GB0304524D0 (en) | Therapeutic agents | |
| GB0307333D0 (en) | Therapeutic agent | |
| GB0325957D0 (en) | The treatment of pain | |
| TW576207U (en) | Improved structure of therapeutic device | |
| GB0301124D0 (en) | Therapeutic methods | |
| GB0310402D0 (en) | Therapeutic agent | |
| GB0303084D0 (en) | Chrystalline therapeutic agent | |
| GB0307335D0 (en) | Therapeutic agent | |
| EP1627632A4 (en) | Therapeutic agent | |
| GB0322014D0 (en) | The treatment of pain |